Expression of KL-6/MUC1 in pancreatic ductal carcinoma and its potential relationship with β-catenin in tumor progression.

[1]  Wei Tang,et al.  Clinicopathology of sialomucin: MUC1, particularly KL-6 mucin, in gastrointestinal, hepatic and pancreatic cancers. , 2009, Bioscience trends.

[2]  Y. Sugawara,et al.  Expression of KL-6 mucin, a human MUC1 mucin, in intrahepatic cholangiocarcinoma and its potential involvement in tumor cell adhesion and invasion. , 2009, Life sciences.

[3]  M. Makuuchi,et al.  Elevation of serum KL-6 mucin levels in patients with cholangiocarcinoma. , 2008, Hepato-gastroenterology.

[4]  N. Kokudo,et al.  Effect of benzyl-N-acetyl-α-galactosaminide on KL-6 mucin expression and invasive properties of a human pancreatic carcinoma cell line. , 2008, Drug discoveries & therapeutics.

[5]  J. Kench,et al.  Stabilization of beta-catenin induces pancreas tumor formation. , 2008, Gastroenterology.

[6]  M. Makuuchi,et al.  Clinical significance of subcellular localization of KL-6 mucin in primary colorectal adenocarcinoma and metastatic tissues. , 2006, World journal of gastroenterology.

[7]  L. Yin,et al.  MUC1 Oncoprotein Blocks Glycogen Synthase Kinase 3β–Mediated Phosphorylation and Degradation of β-Catenin , 2005 .

[8]  M. Makuuchi,et al.  KL-6 mucin expression in carcinoma of the ampulla of Vater: association with cancer progression. , 2005, World journal of gastroenterology.

[9]  J. Behrens.  The role of the Wnt signalling pathway in colorectal tumorigenesis. , 2005, Biochemical Society transactions.

[10]  R. Schmid,et al.  Pancreatic cancer: basic and clinical aspects. , 2005, Gastroenterology.

[11]  D. Kufe,et al.  The MUC1 Oncoprotein Activates the Anti-apoptotic Phosphoinositide 3-Kinase/Akt and Bcl-xL Pathways in Rat 3Y1 Fibroblasts* , 2004, Journal of Biological Chemistry.

[12]  S. George,et al.  MMPs, cadherins, and cell proliferation. , 2004, Trends in cardiovascular medicine.

[13]  D. Kufe,et al.  MUC1 Cytoplasmic Domain Coactivates Wnt Target Gene Transcription and Confers Transformation , 2003, Cancer biology & therapy.

[14]  M. Hollingsworth,et al.  Nuclear Association of the Cytoplasmic Tail of MUC1 and β-Catenin* , 2003, Journal of Biological Chemistry.

[15]  L. Yin,et al.  Human MUC1 Carcinoma Antigen Regulates Intracellular Oxidant Levels and the Apoptotic Response to Oxidative Stress* , 2003, Journal of Biological Chemistry.

[16]  Celeste M Nelson,et al.  VE-cadherin simultaneously stimulates and inhibits cell proliferation by altering cytoskeletal structure and tension , 2003, Journal of Cell Science.

[17]  J. Meza,et al.  Contribution of the MUC1 tandem repeat and cytoplasmic tail to invasive and metastatic properties of a pancreatic cancer cell line. , 2003, Cancer research.

[18]  S. Gendler,et al.  MUC1 alters β-catenin-dependent tumor formation and promotes cellular invasion , 2003, Oncogene.

[19]  J. Lüttges,et al.  The Mucin Profile of Noninvasive and Invasive Mucinous Cystic Neoplasms of the Pancreas , 2002, The American journal of surgical pathology.

[20]  L. Yin,et al.  The Epidermal Growth Factor Receptor Regulates Interaction of the Human DF3/MUC1 Carcinoma Antigen with c-Src and β-Catenin* , 2001, The Journal of Biological Chemistry.

[21]  R. Foisner,et al.  E-cadherin regulates cell growth by modulating proliferation-dependent β-catenin transcriptional activity , 2001, The Journal of cell biology.

[22]  D. Kufe,et al.  Interaction of Glycogen Synthase Kinase 3β with the DF3/MUC1 Carcinoma-Associated Antigen and β-Catenin , 1998, Molecular and Cellular Biology.

[23]  D. Carter.  TNM Classification of Malignant Tumors , 1998 .

[24]  Richard A. Szucs,et al.  TNM Classification of Malignant Tumors. 5th ed , 1998 .

[25]  A. Sonnenberg,et al.  Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components , 1995, The Journal of cell biology.

[26]  N. Kohno,et al.  Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma. , 1988, Japanese journal of clinical oncology.

[27]  Wei Zhang,et al.  Positive KL-6 mucin expression combined with decreased membranous beta-catenin expression indicates worse prognosis in colorectal carcinoma. , 2008, Oncology reports.

[28]  L. Yin,et al.  MUC1 oncoprotein blocks glycogen synthase kinase 3beta-mediated phosphorylation and degradation of beta-catenin. , 2005, Cancer research.

[29]  Michael A. Hollingsworth,et al.  Mucins in cancer: protection and control of the cell surface , 2004, Nature Reviews Cancer.

[30]  M. Hollingsworth,et al.  Nuclear association of the cytoplasmic tail of MUC1 and beta-catenin. , 2003, The Journal of biological chemistry.

[31]  S. Gendler,et al.  MUC1 alters beta-catenin-dependent tumor formation and promotes cellular invasion. , 2003, Oncogene.

[32]  L. Yin,et al.  The epidermal growth factor receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and beta-catenin. , 2001, The Journal of biological chemistry.

[33]  N. Kohno,et al.  Difference in sero‐diagnostic values among KL‐6‐associated mucins classified as cluster 9 , 1994, International journal of cancer. Supplement = Journal international du cancer. Supplement.

[34]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.